View ValuationBirzeit Pharmaceuticals 将来の成長Future 基準チェック /06現在、 Birzeit Pharmaceuticalsの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長15.0%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesBoard Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 5 highly experienced directors. No independent directors (8 non-independent directors). Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.お知らせ • Apr 10+ 1 more updateBirzeit Pharmaceuticals Company announces Annual dividend, payable on July 15, 2026Birzeit Pharmaceuticals Company announced Annual dividend of USD 0.0500 per share payable on July 15, 2026, ex-date on May 06, 2026 and record date on May 07, 2026.Board Change • Jun 10No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 8 non-independent directors. Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 25Birzeit Pharmaceuticals Company announces Annual dividend, payable on May 15, 2025Birzeit Pharmaceuticals Company announced Annual dividend of USD 0.0500 per share payable on May 15, 2025, ex-date on April 23, 2025 and record date on April 24, 2025.Board Change • Apr 15No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 8 non-independent directors. Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.お知らせ • Apr 09Birzeit Pharmaceuticals Company, Annual General Meeting, Apr 22, 2025Birzeit Pharmaceuticals Company, Annual General Meeting, Apr 22, 2025. Location: ramallah Palestinian AuthorityBoard Change • Feb 26No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 8 non-independent directors. Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Oct 29New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.7% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.7% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.8% net profit margin).Reported Earnings • Aug 15Second quarter 2024 earnings released: EPS: US$0.038 (vs US$0.04 in 2Q 2023)Second quarter 2024 results: EPS: US$0.038 (down from US$0.04 in 2Q 2023). Revenue: US$8.36m (down 23% from 2Q 2023). Net income: US$1.48m (down 11% from 2Q 2023). Profit margin: 18% (up from 15% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.New Risk • Jun 13New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 39% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (4.9% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.9% net profit margin).Reported Earnings • Jun 13First quarter 2024 earnings released: US$0.04 loss per share (vs US$0.046 profit in 1Q 2023)First quarter 2024 results: US$0.04 loss per share (down from US$0.046 profit in 1Q 2023). Revenue: US$9.07m (down 11% from 1Q 2023). Net loss: US$1.44m (down 181% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.New Risk • Jun 11New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.5% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (5.0% average weekly change).Reported Earnings • Feb 28Full year 2023 earnings released: EPS: US$0.16 (vs US$0.20 in FY 2022)Full year 2023 results: EPS: US$0.16 (down from US$0.20 in FY 2022). Revenue: US$43.1m (down 8.3% from FY 2022). Net income: US$6.12m (down 23% from FY 2022). Profit margin: 14% (down from 17% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.Buy Or Sell Opportunity • Feb 13Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 5.8% to US$4.23. The fair value is estimated to be US$3.51, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.8% over the last 3 years. Earnings per share has declined by 7.4%.Board Change • Jan 29No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Nov 01No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Aug 15Second quarter 2023 earnings released: EPS: US$0.04 (vs US$0.059 in 2Q 2022)Second quarter 2023 results: EPS: US$0.04 (down from US$0.059 in 2Q 2022). Revenue: US$10.9m (down 2.7% from 2Q 2022). Net income: US$1.67m (down 28% from 2Q 2022). Profit margin: 15% (down from 21% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.Upcoming Dividend • Apr 05Upcoming dividend of US$0.10 per share at 2.4% yieldEligible shareholders must have bought the stock before 12 April 2023. Payment date: 11 June 2023. Payout ratio is a comfortable 20% but the company is not cash flow positive. Trailing yield: 2.4%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (6.0%). Higher than average of industry peers (1.7%).Board Change • Nov 18No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Aug 14Second quarter 2022 earnings released: EPS: US$0.063 (vs US$0.13 in 2Q 2021)Second quarter 2022 results: EPS: US$0.063 (down from US$0.13 in 2Q 2021). Revenue: US$11.2m (down 16% from 2Q 2021). Net income: US$2.30m (down 53% from 2Q 2021). Profit margin: 21% (down from 37% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 18% per year and the company’s share price has also increased by 18% per year.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Upcoming Dividend • Apr 14Upcoming dividend of US$0.10 per shareEligible shareholders must have bought the stock before 21 April 2022. Payment date: 19 June 2022. Payout ratio is a comfortable 24% but the company is paying out more than the cash it is generating. Trailing yield: 3.1%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (5.5%). Higher than average of industry peers (1.7%).Reported Earnings • Feb 21Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: US$45.5m (up 27% from FY 2020). Net income: US$12.1m (up 64% from FY 2020). Profit margin: 27% (up from 21% in FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 6% per year.Board Change • Feb 21No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Reported Earnings • Feb 18Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: US$45.5m (up 27% from FY 2020). Net income: US$12.1m (up 64% from FY 2020). Profit margin: 27% (up from 21% in FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 4% per year.Reported Earnings • Jun 05First quarter 2021 earnings released: EPS US$0.05 (vs US$0.093 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$7.58m (down 9.9% from 1Q 2020). Net income: US$908.0k (down 50% from 1Q 2020). Profit margin: 12% (down from 22% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、Birzeit Pharmaceuticals は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測PLSE:BPC - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2025481202N/A9/30/2025471325N/A6/30/2025461347N/A3/31/202542857N/A12/31/202441557N/A9/30/202438445N/A6/30/202440358N/A3/31/202442369N/A12/31/2023436912N/A9/30/2023446813N/A6/30/202345669N/A3/31/202345726N/A12/31/202247825N/A9/30/20224710-20N/A6/30/2022481223N/A3/31/2022501435N/A12/31/2021451234N/A9/30/2021431199N/A6/30/2021401067N/A3/31/202135766N/A12/31/202036756N/A9/30/202035846N/A6/30/202035848N/A3/31/202035859N/A12/31/20193510711N/A9/30/2019338N/A9N/A6/30/2019327N/A5N/A3/31/2019358N/A9N/A12/31/2018368N/A9N/A9/30/20183510N/A11N/A6/30/20183410N/A12N/A3/31/20183311N/A10N/A12/31/20173311N/A9N/A9/30/2017348N/A4N/A6/30/2017349N/A6N/A3/31/2017348N/A5N/A12/31/2016328N/A5N/A9/30/2016306N/A8N/A6/30/2016285N/A6N/A3/31/2016285N/A6N/A12/31/2015265N/A5N/A9/30/2015275N/A8N/A6/30/2015275N/A8N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: BPCの予測収益成長が 貯蓄率 ( 15.1% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: BPCの収益がPS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: BPCの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: BPCの収益がPS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: BPCの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: BPCの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/21 15:09終値2026/05/10 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Birzeit Pharmaceuticals Company 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Board Change • May 20No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 5 highly experienced directors. No independent directors (8 non-independent directors). Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
お知らせ • Apr 10+ 1 more updateBirzeit Pharmaceuticals Company announces Annual dividend, payable on July 15, 2026Birzeit Pharmaceuticals Company announced Annual dividend of USD 0.0500 per share payable on July 15, 2026, ex-date on May 06, 2026 and record date on May 07, 2026.
Board Change • Jun 10No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 8 non-independent directors. Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 25Birzeit Pharmaceuticals Company announces Annual dividend, payable on May 15, 2025Birzeit Pharmaceuticals Company announced Annual dividend of USD 0.0500 per share payable on May 15, 2025, ex-date on April 23, 2025 and record date on April 24, 2025.
Board Change • Apr 15No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 8 non-independent directors. Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
お知らせ • Apr 09Birzeit Pharmaceuticals Company, Annual General Meeting, Apr 22, 2025Birzeit Pharmaceuticals Company, Annual General Meeting, Apr 22, 2025. Location: ramallah Palestinian Authority
Board Change • Feb 26No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 8 non-independent directors. Director Mohammad Hussein Nasereddin was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Oct 29New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.7% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 8.7% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.8% net profit margin).
Reported Earnings • Aug 15Second quarter 2024 earnings released: EPS: US$0.038 (vs US$0.04 in 2Q 2023)Second quarter 2024 results: EPS: US$0.038 (down from US$0.04 in 2Q 2023). Revenue: US$8.36m (down 23% from 2Q 2023). Net income: US$1.48m (down 11% from 2Q 2023). Profit margin: 18% (up from 15% in 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
New Risk • Jun 13New minor risk - Earnings qualityThe company has large one-off items impacting its financial results. One-off items were 39% of the size of the rest of the company's trailing 12-month earnings before tax. This is considered a minor risk. One-off items are incomes or expenses that the company does not expect to repeat in future periods. Examples include profits from the sale of a business or expenses from a restructuring or legal settlements. If the company's reported statutory earnings include a large proportion of one-off items it means they may be an unreliable indicator of its true business performance as the earnings were skewed by these incomes or expenses. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 4.6% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (4.9% average weekly change). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (6.9% net profit margin).
Reported Earnings • Jun 13First quarter 2024 earnings released: US$0.04 loss per share (vs US$0.046 profit in 1Q 2023)First quarter 2024 results: US$0.04 loss per share (down from US$0.046 profit in 1Q 2023). Revenue: US$9.07m (down 11% from 1Q 2023). Net loss: US$1.44m (down 181% from profit in 1Q 2023). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has increased by 14% per year, which means it is well ahead of earnings.
New Risk • Jun 11New minor risk - Dividend sustainabilityThe company has an unstable dividend paying track record. The dividend has had an annual drop of over 20% in the past. Dividend yield: 2.5% This is considered a minor risk. If the company has cut or reduced its dividend in the past, it may be a sign that the underlying business is too cyclical to consistently maintain or grow the dividend over the long-term. It may also indicate the company prioritizes other outcomes instead of maintaining the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 0.6% per year over the past 5 years. Minor Risks Unstable dividend paying track record with dividend experiencing an annual drop of over 20% in the past. Share price has been volatile over the past 3 months (5.0% average weekly change).
Reported Earnings • Feb 28Full year 2023 earnings released: EPS: US$0.16 (vs US$0.20 in FY 2022)Full year 2023 results: EPS: US$0.16 (down from US$0.20 in FY 2022). Revenue: US$43.1m (down 8.3% from FY 2022). Net income: US$6.12m (down 23% from FY 2022). Profit margin: 14% (down from 17% in FY 2022). The decrease in margin was driven by lower revenue. Over the last 3 years on average, earnings per share has fallen by 13% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.
Buy Or Sell Opportunity • Feb 13Now 21% overvalued after recent price riseOver the last 90 days, the stock has risen 5.8% to US$4.23. The fair value is estimated to be US$3.51, however this is not to be taken as a sell recommendation but rather should be used as a guide only. Revenue has grown by 8.8% over the last 3 years. Earnings per share has declined by 7.4%.
Board Change • Jan 29No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Nov 01No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 15Second quarter 2023 earnings released: EPS: US$0.04 (vs US$0.059 in 2Q 2022)Second quarter 2023 results: EPS: US$0.04 (down from US$0.059 in 2Q 2022). Revenue: US$10.9m (down 2.7% from 2Q 2022). Net income: US$1.67m (down 28% from 2Q 2022). Profit margin: 15% (down from 21% in 2Q 2022). The decrease in margin was primarily driven by higher expenses. Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has increased by 18% per year, which means it is well ahead of earnings.
Upcoming Dividend • Apr 05Upcoming dividend of US$0.10 per share at 2.4% yieldEligible shareholders must have bought the stock before 12 April 2023. Payment date: 11 June 2023. Payout ratio is a comfortable 20% but the company is not cash flow positive. Trailing yield: 2.4%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (6.0%). Higher than average of industry peers (1.7%).
Board Change • Nov 18No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Aug 14Second quarter 2022 earnings released: EPS: US$0.063 (vs US$0.13 in 2Q 2021)Second quarter 2022 results: EPS: US$0.063 (down from US$0.13 in 2Q 2021). Revenue: US$11.2m (down 16% from 2Q 2021). Net income: US$2.30m (down 53% from 2Q 2021). Profit margin: 21% (down from 37% in 2Q 2021). Over the last 3 years on average, earnings per share has increased by 18% per year and the company’s share price has also increased by 18% per year.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Upcoming Dividend • Apr 14Upcoming dividend of US$0.10 per shareEligible shareholders must have bought the stock before 21 April 2022. Payment date: 19 June 2022. Payout ratio is a comfortable 24% but the company is paying out more than the cash it is generating. Trailing yield: 3.1%. Lower than top quartile of Palestinian Territory, Occupied dividend payers (5.5%). Higher than average of industry peers (1.7%).
Reported Earnings • Feb 21Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: US$45.5m (up 27% from FY 2020). Net income: US$12.1m (up 64% from FY 2020). Profit margin: 27% (up from 21% in FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 6% per year.
Board Change • Feb 21No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 6 highly experienced directors. No independent directors (7 non-independent directors). Director Salem Mostafa Salem Khaizaran was the last director to join the board, commencing their role in 2011. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Reported Earnings • Feb 18Full year 2021 earnings: Revenues in line with analyst expectationsFull year 2021 results: Revenue: US$45.5m (up 27% from FY 2020). Net income: US$12.1m (up 64% from FY 2020). Profit margin: 27% (up from 21% in FY 2020). Revenue was in line with analyst estimates. Over the last 3 years on average, earnings per share has increased by 7% per year whereas the company’s share price has increased by 4% per year.
Reported Earnings • Jun 05First quarter 2021 earnings released: EPS US$0.05 (vs US$0.093 in 1Q 2020)The company reported a poor first quarter result with weaker earnings, revenues and profit margins. First quarter 2021 results: Revenue: US$7.58m (down 9.9% from 1Q 2020). Net income: US$908.0k (down 50% from 1Q 2020). Profit margin: 12% (down from 22% in 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has only fallen by 1% per year, which means it has not declined as severely as earnings.